RUBY - Rubius Therapeutics falls 45% after updated early-stage data on solid tumors candidate

Shares of Rubius Therapuetics (NASDAQ:RUBY) tumbled 45% Friday after the company released updated phase 1/2 data on RTX-240 for advanced solid tumors. Partial responses were seen in some patients with non-small cell lung cancer ("NSCLC"), metastatic anal cancer, and metastatic uveal melanoma. The candidate was found to be well tolerated with no treatment-related or investigator-identified immune-related Grade 3/4 adverse events (AEs) and no dose-limiting toxicities. Rubius also said it will report phase 1 clinical results for RTX-240 in combination with pembrolizumab in advanced solid tumors and data from additional NSCLC and renal cell carcinoma patients in the second half of the year. Initial phase 1 results for RTX-321 for HPV 16-positive cancers will also be released in the second half of the year. In March, Seeking Alpha contributor Avisol Capital Partners argued that Rubius (RUBY) was a buy.

For further details see:

Rubius Therapeutics falls 45% after updated early-stage data on solid tumors candidate